We scan new podcasts and send you the top 5 insights daily.
Patients receiving sacituzumab govitecan frequently face neutropenia and diarrhea, especially when heavily pretreated. Dr. Abraham recommends initiating treatment at the full 10 mg/kg dose on days one and eight, followed by dose reductions to 7.5 mg/kg or day-eight Neulastra administration to allow one recovery week.
While CELMoDs frequently cause neutropenia, this effect is most pronounced in early cycles and manageable with growth factors. This contrasts sharply with the persistent, quality-of-life-impairing non-hematologic side effects of lenalidomide, such as rash and severe fatigue. This trade-off results in a significantly better long-term tolerability profile for patients.
Studies demonstrated that prophylactic loperamide led to severe constipation during sacituzumab govitecan treatment. Dr. Tolaney advises reserving loperamide strictly for as-needed use, while prioritizing growth factor prophylaxis on days two through four and day eight for patients at high risk of neutropenia.
Topoisomerase I payloads in ADCs carry a high risk of neutropenia, a toxicity that has caused previous trials to fail. Future Phase 3 studies, particularly in prostate cancer, must incorporate proactive management strategies like prophylactic GCSF to mitigate this risk, which is considered a critical success factor.
Initial concerns about severe diarrhea with sacituzumab govitecan are now less relevant due to improved management. Prophylactic use of strong antiemetic regimens often causes constipation, effectively preventing diarrhea and dramatically improving the drug's tolerability based on clinical experience.
While these drugs can cause neutropenia, it rarely leads to infections. Patients often feel clinically well despite low neutrophil counts. This 'paper problem' can usually be managed with G-CSF without needing to dose-reduce the primary CLL therapy.
To manage the high risk of neutropenia with sacituzumab govitecan, prophylactic growth factor (G-CSF) use is becoming standard clinical practice. This is particularly true after the Day 8 administration. For some populations, like Asian patients, it is considered mandatory from the start, sometimes with a dose reduction.
Despite the trial protocol specifying day 1 and day 8 dosing for the ADC Sacituzumab Govitecan (SG), community practitioners are frequently using a day 1 and day 15 schedule. This real-world adaptation is happening anecdotally to manage toxicity, with formal prospective studies still ongoing to validate the approach.
Prophylactic G-CSF is used with sacituzumab govitecan not only to prevent febrile neutropenia but for practical reasons. It helps ensure patients' blood counts recover for their Day 8 dose, preventing treatment delays and simplifying scheduling for busy infusion centers.
Proactive management of topoisomerase-1 ADC payload toxicities requires upgrading antiemetic regimens by adding neurokinin-1 inhibitors such as aprepitant to standard ondansetron and dexamethasone. Dr. Alvarez-Secord also utilizes upfront growth factor support for at-risk patients and prompt anti-motility treatment to prevent dose interruptions.
A patient in the BELLA trial with recurrent grade 3 neutropenia avoided treatment discontinuation through dose modification. By skipping the day 8 dose and switching to a day 1 and 15 every 28-day schedule, the patient could tolerate and continue the beneficial therapy, showcasing a practical clinical strategy for managing severe toxicity.